Remdesivir News and Research

RSS

Could the marine compound plitidepsin promote recovery from moderate COVID-19?

A new paper by an international team of researchers describes experimental evidence of the antiviral efficacy of a marine compound called plitidepsin against SARS-CoV-2. The findings show that plitidepsin inhibits SARS-CoV at low concentrations, as observed by a thousand-fold reduction in genomic RNA and viral titers in cells exposed to the virus in culture when treated.

27 May 2021

Study details challenges and progress toward creating a COVID-19 drug

The COVID-19 pandemic has seen scientists perform incredible feats in a short amount of time, from developing tests to new types of vaccines.

26 May 2021

‘Better than the hospital’: Pandemic boosts care for serious illnesses at home

Late last year, Janet Yetenekian was one of the thousands of people in Southern California whose case of covid-19 was serious enough to send her to the hospital.

26 May 2021

Repurposed gout medication (probenecid) shows potent inhibition of SARS-CoV-2 replication

New research by a team of scientists in the USA describes the potential utility of a drug called probenecid, commonly used to treat gout, to treat this devastating viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the causative virus of COVID-19.

25 May 2021

Genetically engineered intestinal organoids reveal potential treatment targets against SARS-CoV-2

Using CRISPR/Cas9 and human intestinal organoids to study genes implicated in the biology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), researchers from the Netherlands identified a specific serine protease (TMPRSS2) as an attractive pan-coronavirus therapeutic target. Their exciting findings are available in a study currently available on the bioRxiv* preprint server.

24 May 2021

Investigators map how drugs were used on people hospitalized with COVID-19 infection

A record of medicine utilization patterns assembled by an interdisciplinary team of researchers at the University of California, Irvine and the UC San Diego School of Medicine reveals the thought, care and scientific rigor clinicians at UC Health medical centers applied in their treatment of patients with COVID-19 in 2020.

21 May 2021

Novel broad-spectrum antiviral compounds effective against Zika and SARS-CoV-2

A research team at the University of Alberta, Canada, led by Dr. Daniel Limonta, has described two novel molecules with broad antiviral properties that are effective against a range of virus types, including SARS-CoV-2.

21 May 2021

Facets of SARS-CoV-2 infection and animal models

A new study in the journal Frontiers in Cell and Developmental Biology discusses the ribonucleic acid (RNA) genome of the virus, and the mechanisms by which it establishes infection within the host cell. The researchers also summarize the development of animal models of COVID-19, which will both help understand the clinical features of the illness, and indicate new approaches for the treatment of the infection.

21 May 2021

Could graphene oxide nanosheets be an effective SARS-CoV-2 antiviral in PPE?

A new study has been published in Small, which has combined in silico and in vitro analysis to examine if graphene oxide (GO) sheets have an inhibitory effect against SARS‐CoV‐2 surface proteins.

20 May 2021

To the bat cave: In search of covid’s origins, scientists reignite polarizing debate on Wuhan ‘lab leak’

Once dismissed as a conspiracy theory, the idea that the covid virus escaped from a Chinese lab is gaining high-profile attention. As it does, reputations of renowned scientists are at risk — and so is their personal safety.

19 May 2021

Glucosidase inhibitors hold promise as novel therapeutic agents against SARS-CoV-2

In a new study posted to the bioRxiv* preprint server, researchers from the United States report that two iminosugar glucosidase inhibitors have the ability to suppress the replication of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in tissue culture – at concentrations of at least 100 times lower than required for cytotoxic effects.

19 May 2021

Scientists develop experimental direct-acting antiviral therapy to treat COVID-19

An international team of scientists from the Menzies Health Institute Queensland (MHIQ) at Griffith University and from City of Hope, a research and treatment center for cancer, diabetes and other life-threatening diseases in the U.S., have developed an experimental direct-acting antiviral therapy to treat COVID-19.

18 May 2021

ErbB inhibitor lapatinib exhibits potent anti-SARS-CoV-2 activity

A team of scientists from the USA and Belgium has recently revealed that the ErbB family of receptor tyrosine kinases play a vital role in regulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lifecycle in host cells and that inhibition of these receptors can protect against SARS-CoV-2-induced acute and chronic lung injuries and inflammation.

18 May 2021

Researchers use ultrasound to reduce COVID-19-related inflammation

Researchers at University of California San Diego School of Medicine have begun a pilot clinical trial to test the efficacy of using ultrasound to stimulate the spleen and reduce COVID-19-related inflammation, decreasing the length of hospital stays.

13 May 2021

Study reveals how oral antiviral drug works to attack SARS-CoV-2 virus

A University of Alberta virology lab has uncovered how an oral antiviral drug works to attack the SARS-CoV-2 virus, in findings published May 10 in the Journal of Biological Chemistry.

12 May 2021

Researchers design compounds that prevent SARS-CoV-2 entry in human lung cells

Researchers have designed a new class of TMPRSS2 inhibitors that have shown broad antiviral activity against coronaviruses, including the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

11 May 2021

Researchers discover the second possible effective mechanism of remdesivir

The virostatic agent remdesivir was developed to disrupt an important step in the propagation of RNA viruses, to which SARS-CoV-2 also belongs: the reproduction of the virus's own genetic material. This is present as RNA matrices with which the host cell directly produces virus proteins.

11 May 2021

Researchers identify anti-inflammatory prodrug Minnelide with potential against SARS-CoV-2

Using a transgenic mouse model of COVID-19, they have observed that treatment with Minnelide reduces viral load and inflammation in the lungs and improves survival. The study is currently available on the bioRxiv* preprint server.

9 May 2021

Immunosuppression in COVID-19 promotes emergence of multiple immune escape mutants

An interesting new study describes the emergence of several such variants from a chronically immunosuppressed COVID-19 patient, who remained infected for over 170 days before clearing the virus.

7 May 2021

Researchers identify potent small molecule TMPRSS2 inhibitor against SARS-CoV-2

A team of scientists from the USA and Canada has recently identified and characterized a novel small-molecule compound inhibitor of cellular serine protease TMPRSS2, which shows significant antiviral potency against emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

5 May 2021

Remdesivir News and Research

Could the marine compound plitidepsin promote recovery from moderate COVID-19?

Study details challenges and progress toward creating a COVID-19 drug

‘Better than the hospital’: Pandemic boosts care for serious illnesses at home

Repurposed gout medication (probenecid) shows potent inhibition of SARS-CoV-2 replication

Genetically engineered intestinal organoids reveal potential treatment targets against SARS-CoV-2

Investigators map how drugs were used on people hospitalized with COVID-19 infection

Novel broad-spectrum antiviral compounds effective against Zika and SARS-CoV-2

Facets of SARS-CoV-2 infection and animal models

Could graphene oxide nanosheets be an effective SARS-CoV-2 antiviral in PPE?

To the bat cave: In search of covid’s origins, scientists reignite polarizing debate on Wuhan ‘lab leak’

Glucosidase inhibitors hold promise as novel therapeutic agents against SARS-CoV-2

Scientists develop experimental direct-acting antiviral therapy to treat COVID-19

ErbB inhibitor lapatinib exhibits potent anti-SARS-CoV-2 activity

Researchers use ultrasound to reduce COVID-19-related inflammation

Study reveals how oral antiviral drug works to attack SARS-CoV-2 virus

Researchers design compounds that prevent SARS-CoV-2 entry in human lung cells

Researchers discover the second possible effective mechanism of remdesivir

Researchers identify anti-inflammatory prodrug Minnelide with potential against SARS-CoV-2

Immunosuppression in COVID-19 promotes emergence of multiple immune escape mutants

Researchers identify potent small molecule TMPRSS2 inhibitor against SARS-CoV-2

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News